Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom

Overview of attention for article published in The Journal of Headache and Pain, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 2 policy sources

twitter: 1 X user

Citations

dimensions_citation: 100 Dimensions

Readers on

mendeley: 153 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 4 policy documents that reference this research output.

galcanezumab

Cited by Canadian Agency for Drugs and Technologies in Health on 28 Feb 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Galcanezumab for preventing migraine

Cited by National Institute for Health and Care Excellence on 18 Nov 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Galcanezumab for preventing migraine : Committee papers

Cited by National Institute for Health and Care Excellence on 08 Oct 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Fremanezumab for preventing migraine : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 08 Nov 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.